Related Experiment Videos
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
C M Celluzzi1, J I Mayordomo, W J Storkus
1Department of Dermatology, University of Pittsburgh Medical Center, Pennsylvania 15213, USA.
The Journal of Experimental Medicine
|January 1, 1996
Summary
Tumor-specific immunity can be induced using dendritic cells (DCs) pulsed with tumor antigens. This approach primes cytotoxic T lymphocytes (CTLs) to target and eliminate tumors, offering a potential strategy for cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Cellular Biology
Background:
- Cytotoxic T lymphocytes (CTLs) are crucial for anti-tumor immunity.
- Tumor-specific antigens are key targets for CTL-mediated cancer rejection.
- Dendritic cells (DCs) are potent antigen-presenting cells (APCs) that prime CTL responses.
Purpose of the Study:
- To investigate if pulsing dendritic cells (DCs) with tumor antigens can induce protective anti-tumor immunity.
- To determine the antigen specificity and T cell dependence of this induced immunity.
- To assess the potential of antigen-pulsed DCs as a cancer immunotherapy strategy.
Main Methods:
- Dendritic cells (DCs) were pulsed with peptide antigens derived from tumors.
- Mice were immunized with antigen-pulsed DCs.
- Immunized mice were challenged with tumors transfected with the antigen gene.
- Immune response was assessed by tumor rejection and CD8+ T cell depletion.
- Protection against subsequent challenge with parent tumor was evaluated.
Main Results:
- Immunization with antigen-pulsed DCs induced protective immunity against lethal tumor challenge.
- The induced immunity was antigen-specific, dependent on tumor antigen expression.
- Immunity was mediated by CD8+ T cells, as depletion eliminated protection.
- Mice that rejected tumors were protected from subsequent challenge with the parent tumor line.
Conclusions:
- Antigen-pulsed DCs can effectively induce antigen-specific, CTL-mediated anti-tumor immunity.
- This strategy holds promise for developing effective cancer immunotherapies.
- Further research into DC-based vaccines for cancer is warranted.